We are live on ! Find out more
IPSC icon

Century Therapeutics
IPSC

47 hedge funds and large institutions have $25.6M invested in Century Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more capital invested

Capital invested by funds: $10.1M → $25.6M (+$15.5M)

5.91% more ownership

Funds ownership: 23.5% → 29.42% (+5.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

18% less funds holding

Funds holding: 57 → 47 (-10)

36% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 14

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
47
Holders Change
-10
Holders Change %
-17.54%
% of All Funds
0.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
9
Reduced
14
Closed
16
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.64M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.12M
3
DCM
DAFNA Capital Management
California
+$665K
4
Two Sigma Investments
Two Sigma Investments
New York
+$357K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$303K

Top Sellers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$1.76M
2
Renaissance Technologies
Renaissance Technologies
New York
-$755K
3
TCM
Tang Capital Management
California
-$448K
4
GCP
GSA Capital Partners
United Kingdom
-$165K
5
Squarepoint
Squarepoint
New York
-$118K
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
1
Point72 Asset Management
Connecticut
$5.93M +$3.64M +5,961,631 New
DCM
2
DAFNA Capital Management
California
$2.78M +$665K +1,089,354 +64%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.09M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$1.83M +$1.12M +1,838,700 New
Two Sigma Investments
5
Two Sigma Investments
New York
$1.49M +$357K +584,470 +64%
SSC
6
Spruce Street Capital
New York
$1.41M +$867K +1,421,532 New
Renaissance Technologies
7
Renaissance Technologies
New York
$1.34M -$755K -1,237,700 -48%
Two Sigma Advisers
8
Two Sigma Advisers
New York
$1.26M +$250K +410,100 +48%
CC
9
Casdin Capital
New York
$1.22M – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$1.21M +$303K +497,295 +69%
SP
11
Syncona Portfolio
Guernsey
$1.21M – – –
Millennium Management
12
Millennium Management
New York
$607K -$81.4K -133,394 -18%
BlackRock
13
BlackRock
New York
$599K +$1.35K +2,210 +0.4%
SCM
14
Superstring Capital Management
New York
$461K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$454K +$6.59K +10,806 +2%
GCP
16
GSA Capital Partners
United Kingdom
$331K -$165K -270,280 -45%
Citadel Advisors
17
Citadel Advisors
Florida
$318K -$25.2K -41,368 -11%
UBS Group
18
UBS Group
Switzerland
$213K +$131K +214,164 +63,550%
State Street
19
State Street
Massachusetts
$127K – – –
Northern Trust
20
Northern Trust
Illinois
$105K +$23.2K +38,052 +57%
Raymond James Financial
21
Raymond James Financial
Florida
$90.8K – – –
AG
22
Algert Global
California
$76K +$46.8K +76,800 New
Fidelity Investments
23
Fidelity Investments
Massachusetts
$71.2K -$73.6K -120,599 -63%
Wealth Enhancement Advisory Services
24
Wealth Enhancement Advisory Services
Minnesota
$70K -$34 -56 -0.1%
Prudential Financial
25
Prudential Financial
New Jersey
$59.5K – – –
1
2 3

IPSC Hedge Fund Activity: Q4 2025 in Review

47 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2025, worth a combined $25.6M — up 153% from $10.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of IPSC and 8 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 9 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.64M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.76M sold.

  • 47 institutional investors held Century Therapeutics (IPSC) as of Q4 2025, down from 57 in Q3 2025.
  • Funds reported $25.6M of Century Therapeutics stock for Q4 2025, up 153% quarter-over-quarter.
  • 8 funds opened new Century Therapeutics positions in Q4 2025 and 16 closed out, a net change of -8 holders.
  • The largest Century Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $3.64M added.
  • The largest Century Therapeutics seller in Q4 2025 was Bain Capital Life Sciences Investors, an estimated $1.76M sold.

Based on aggregated 13F filings for Q4 2025.